BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines noncurrent Value-Added Tax (VAT) Receivable ($M) ($M)
Form 10-Q / 10-K Balance Sheet Details Note (XBRL)
Latest, Q2 2026
3.80
Period ended Jun 30, 2026
Change on a year earlier
+22.6%
3.10 in Q2 2025
History
33 quarters
Since Q4 2017
Sources
32
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Noncurrent Value-Added Tax (VAT) Receivable ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 3.80 | +22.6% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 3.60 | +16.1% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 3.50 | +20.7% | Form 10-Q (filed 2026-08-05) ↗ |
| Q3 2025 | Sep 30, 2025 | 3.30 | +17.9% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 3.10 | +19.2% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 3.10 | +10.7% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 2.90 | +16.0% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | 2.80 | +40.0% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 2.60 | +52.9% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 2.80 | +100.0% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 2.50 | +212.5% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2023 | Sep 30, 2023 | 2 | +900.0% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2023 | Jun 30, 2023 | 1.70 | – | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 1.40 | -95.5% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 0.80 | -95.3% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2022 | Sep 30, 2022 | 0.20 | -99.1% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 0 | -100.0% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 31 | +84.5% | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2021 | Dec 31, 2021 | 17.2 | +57.8% | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2021 | Sep 30, 2021 | 21.5 | -26.9% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 23.6 | -8.2% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 16.8 | -48.1% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 10.9 | -63.7% | Form 10-K (filed 2022-02-28) ↗ |
| Q3 2020 | Sep 30, 2020 | 29.4 | +14.4% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 25.7 | +12.2% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 31, 2020 | 32.4 | +63.6% | Form 10-Q (filed 2020-05-11) ↗ |
| Q4 2019 | Dec 31, 2019 | 30 | +104.1% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 25.7 | +221.3% | Form 10-Q (filed 2019-11-12) ↗ |
| Q2 2019 | Jun 30, 2019 | 22.9 | – | Form 10-Q (filed 2019-08-08) ↗ |
| Q1 2019 | Mar 31, 2019 | 19.8 | – | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 14.7 | – | Form 10-K (filed 2020-03-02) ↗ |
| Q3 2018 | Sep 30, 2018 | 8 | – | Form 10-Q (filed 2018-11-08) ↗ |
| Q4 2017 | Dec 31, 2017 | 0 | – | Form 10-K (filed 2019-02-28) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Noncurrent Value-Added Tax (VAT) Receivable ($M) ($M), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/vat_rec_nc
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.